IMPORTANCE Second primary malignant neoplasms (SPMNs) are the leading cause of death in survivors of head and neck squamous cell carcinoma (HNSCC). Recently, human papillomavirus (HPV) has emerged as a risk factor for oropharyngeal squamous cell carcinoma and has different prognosis from classic tobacco/alcohol-associated HNSCC. This suggests that there also may be different risks and burden of SPMNs among patients who's HNSCC were from HPV or tobacco and/or alcohol.
T here was an estimated 63 000 new cases of head and neck cancer in the United States in 2017, accounting for about 4% of new cancers. 1 Patients with head and neck squamous cell carcinoma (HNSCC) experience elevated risk of developing second primary malignant neoplasms (SPMNs). [2] [3] [4] [5] [6] [7] These are of increasing concern because the number of survivors of HNSCC has been growing owing to early detection and advances in cancer treatments. 8 There are an estimated 430 000 HNSCC survivors in the United States, and the number is expected to continue to rise. 9 The incidence of SPMN in HNSCC patients is about 3% to 7% per year, with an estimated 20-year cumulative risk of 36%. 5 Approximately one-third of HNSCC deaths are attributable to SPMNs. Second primary malignant neoplasms are the cause of death in 3 times as many patients with HNSCC compared with those who die of metastatic disease. [10] [11] [12] Tobacco and excessive alcohol use, as well as human papillomavirus (HPV) infection, are the main causal factors associated with HNSCC, HPV being mostly associated with a subset of patients with HNSCC called oropharyngeal squamous cell carcinoma (SCC). [13] [14] [15] Although there has been a steady decrease in the incidence of HNSCC associated with tobacco and alcohol, HPV-associated oropharyngeal SCC has increased about 225% in the United States in the past 3 decades and is projected to surpass cervical cancer as the most common HPVassociated cancer by 2020. 16 Human papillomavirusassociated HNSCC, especially oropharyngeal SCC, affects young males, whites, and has a good prognosis, whereas non-HPVassociated HNSCC typically affects older patients and has poor prognosis. [16] [17] [18] [19] Therefore, anatomical subsites of SPMNs following diagnosis of a first HPV-associated HNSCC may also be different from a first non-HPV-associated HNSCC.
Patients with a first HNSCC have an elevated risk of developing an SPMN of the lung, esophagus, and head and neck sites. 3, 5, 7, [20] [21] [22] However, studies have not examined the incidence and sites of SPMNs stratified by a first HPV-associated HNSCC compared with non-HPV-associated HNSCC. Describing subsite-specific risks of SPMNs may have implications for the pattern and intensity of screening and other preventive efforts in patients with HNSCC after diagnosis. In this study, we quantified the risk of SPMN among patients with a first HPV-associated HNSCC vs non-HPVassociated HNSCC, and described the anatomical sites of these SPMNs.
Methods

Data Source and Population
A population-based cohort of all patients (>20 years) with a first HNSCC diagnosed between 2000 and 2014 from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) 18 database, which covers approximately 30% of the US population and includes cases diagnosed from 2000 to 2014, were used for this study. 23 
SPMN Identification
Coding of multiple primary tumors followed the common set of rules proposed by the International Agency for Research on Cancer (IARC). These rules define multiple primary tumors as 2 or more tumors arising in different sites, or at the same site when the histologic findings are different. 29 An SPMN was defined as the first subsequent primary cancer occurring at least 2 months after first cancer diagnosis, similar to other studies. 7, 21, 30 Consequently, the person-year at risk (PYR) for each individual began at 2 months of follow-up, and ended at the date of SPMN diagnosis, last known vital status, death, or the end of the study period of follow-up (December 2014); whichever came first. Extensions, recurrences, metastasis, and third and subsequent cancers were not included.
HPV-Relatedness in Patients With HNSCC
HPV-relatedness was based on whether patients' first HNSCC was potentially associated with HPV. Since the SEER database does not record HPV status, patients with a first potentially HPV-associated HNSCCs were identified using methodology previously described, 14, 15, 31, 32 which is based on ICD-O-3 topography: oropharynx (C100-109), tonsil (lingual and palatine; C024, and C090-099, respectively), base of tongue (C019), and Waldeyer's ring (C142). Patients with a first non-HPV-associated HNSCC were other ICD-O-3 sites, including oral cavity (tongue, C020-023); gum, C030-039; palate, C050-059; other mouth areas, C060-069; lip, C000-009; and floor of mouth, C040-049), hypopharynx (C130-139), and larynx (C320-329).
Statistical Analyses
The standard person-year approach to describe relative and absolute excess risk of developing SPMN was used. 21, 33 
Results
Patient Population
In all, 109 512 patients with first HNSCC were identified in the SEER registry between 2000 and 2014. Incidence and Location of SPMN Among First Potentially HPV-Associated HNSCC The sensitivity analysis (eTable 1 in the Supplement) by limiting the study population to white males in their 20s to 50s showed that the same anatomical sites were at elevated risks of developing SPMN.
Risk of Solid Tumor SPMN
Incidence and Location of SPMN Among First Non-HPV-Associated HNSCC
In all, 8876 SPMNs were observed among patients diagnosed with first non-HPV-associated HNSCC ( and neck (gum and other mouth, floor of mouth, tongue, lip, pharynx, larynx, oropharynx, and hypopharynx), esophagus, lung and bronchus, thyroid, colorectal, liver, and stomach cancers.
Incidence and Location of SPMN by Anatomical Subsite
Discussion
To our knowledge, this is the first population-based analysis of SPMN risk in the United States that examined differences in SPMN by HPV relatedness of the first HNSCC. The burden of SPMN was high in patients with HNSCC, with 160 excess second solid tumors developing per 10 000 PYR. The anatomic sites-head and neck, lung, esophagus-at elevated risk for SPMN were the same irrespective of HPV relatedness of the first HNSCC. However, the risks and excess of SPMNs were lower among patients with a first potentially HPV-associated HN-SCC (114 excess per 10 000 PYR) than those with a first non-HPV-associated HNSCC (188 excess per 10 000 PYR). The lower relative risk and absolute excess among patients with a first potentially HPV-associated HNSCC could be explained by the fact that most patients with HPV-positive SCC tend to have better prognosis and are less likely to use tobacco and alcohol. 16, 17 Among patients with first potentially HPV-associated HN-SCC, lung cancer accounted for the largest proportion of excess second cancer burden followed by tongue, gum, and esophagus, which is consistent with previous findings. 3, 4 There were strongly elevated risk ratios for the development of a head and neck SPMN (gum, floor of mouth, tongue), with SIR values greater than 15. Oncogenic HPV types are associated with cervical, anal, vaginal, vulvar, and penile cancers. 14,39 Aprevious study reported an association between oropharyngeal SCC and the risk of second cancers in these sites, 40 but the present study did not find significantly elevated risks in these sites, consistent with what Neumann et al found. 4 These could be owing to the low prevalence of these cancers in the United States. Also, it could be that the burden of smoking is high among HNSCC patients 41, 42 irrespective of HPV status, which might explain why tobacco-associated cancers such as lung, rather than HPV-associated anogenital cancers, made up most of the SPMNs found in this study. Among patients with first non-HPV-associated HNSCC, there were strongly elevated risk ratios for the development of a head and neck SPMN (gum and floor of mouth), with SIR values of 30 or higher. Second primary lung, tongue, gum, and esophagus cancers accounted for the largest proportion of excess second cancer burden; a finding consistent with previously published population-based studies including an international multicenter study from 13 population-based cancer registries. 4, 5, 7, 20 When looking at subsites separately, patients with index hypopharyngeal SCC had relative risks for SPMN that were highest of any subsite (SIR, 3.0) as well as excess risk (EAR, 303). All subsites-oral cavity, laryngeal, and hypopharyngeal SCCs-were strongly associated with SPMNs in the head and neck with SIRs being as high as 64 for gum among patients with oral cavity SCC. However, largest proportions of excess SPMNs were observed in the lung for all subsites followed by head and neck and esophagus; possibly owing to tobacco and alcohol use. To- bacco and alcohol consumption are estimated to be responsible for 72% of head and neck cancers in the general population. 43 The association of the first HNSCC with SPMNs, particularly with head and neck cancers, has been described in the context of a field cancerization effect, 44 in which carcinogenic effects from tobacco and alcohol on the aerodigestive tract may simultaneously act on other parts, this is believed to elevate epithelial cancer risk through the head and neck, lung, and esophagus. Smoking and drinking habits of patients before the first primary diagnosis play a role in the SPMN occurrence; it will be important to inform cancer patients who continued tobacco or tobacco-related and alcohol use habits of their increase risk of SPMNs, including lung cancer, which subsequently leads to poorer survival.
Implications
Our findings have implications for cancer survivors, clinicians, and public health practitioners. Second primary malignat neoplasms are associated with a poor prognosis, are the leading cause of long-term morbidity and mortality 10- 
Limitations and Strengths
A limitation of this study is the lack of information about HPV status in SEER. We therefore used anatomical sites that are well established for HPV-associated oropharyngeal SCC. 14, 15, 31, 32 Because only 70% to 72% of cancers of these sites are HPV positive, 16, 47 this could have resulted in overestimation of SPMN risks among patients with first potentially HPV-associated HNSCC. However, our sensitivity analysis provided similar results to the main analysis; even though not every patient in the sensitivity analysis would be HPV positive. In addition, our findings are similar to those of 2 single-institution studies that used actual HPV status in patients with oropharyngeal SCC. 17, 50 Likewise, SEER registry data do not record risk factors such as tobacco and/or alcohol use, and we were therefore unable to incorporate these factors into a wider analysis of risk factors for SPMN. Another limitation is the 2-month delay used to define SPMN. We performed sensitivity analyses also using the 6-month definition which provided very similar results to our main results. Finally, we were limited to clinical criteria for SPMN and therefore there could be misclassifications. Lung metastases may be misclassified as SPMNs or vice versa leading to overestimation of SPMN risks. Despite these limitations, strengths of our study included a large sample size, near complete follow-up, and the high quality control of the SEER program. 21, 27 Risks were calculated using a large SEER reference cohort, thus maximizing both internal validity and generalizability of results.
Conclusions
Patients with first potentially HPV-associated HNSCC and also those with non-HPV-associated HNSCC are at increased risks of developing SPMN in the head and neck region as well as lung and esophagus even though the risk and burden were lower among those with potentially HPV-associated HNSCC. These findings could be useful for clinicians in the diagnosis and prevention of subsequent cancers in these patients. Efforts made by public health policy makers and oncology care professionals should be sustained to develop effective smoking cessation interventions. Future studies should evaluate if there are differences in risks of SPMN among patients with HNSCC in earlier years vs later years owing to shifting risk profiles among patients with HNSCC. 
